TC
CLDX icon

TwinBeech Capital’s Celldex Therapeutics CLDX Stock Holding History

TwinBeech Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,445
Closed -$363K – 417
2026
Q1 		$363K Buy
+11,445
New +$312K 0.04% 411
2025
Q3 		– Sell
-23,676
Closed -$482K – 603
2025
Q2 		$482K Sell
23,676
-14,668
-38% -$286K 0.01% 493
2025
Q1 		$696K Buy
38,344
+3,786
+11% +$84.6K 0.01% 538
2024
Q4 		$873K Sell
34,558
-105,944
-75% -$2.88M 0.01% 397
2024
Q3 		$4.78M Buy
140,502
+103,497
+280% +$3.94M 0.09% 260
2024
Q2 		$1.37M Buy
37,005
+18,459
+100% +$696K 0.03% 372
2024
Q1 		$778K Sell
18,546
-18,631
-50% -$765K 0.02% 437
2023
Q4 		$1.47M Sell
37,177
-25,406
-41% -$747K 0.02% 445
2023
Q3 		$1.72M Buy
62,583
+44,207
+241% +$1.39M 0.03% 430
2023
Q2 		$623K Sell
18,376
-25,692
-58% -$866K 0.01% 496
2023
Q1 		$1.59M Buy
+44,068
New +$1.9M 0.03% 398
2022
Q4 		– Sell
-48,939
Closed -$1.38M – 724
2022
Q3 		$1.38M Buy
+48,939
New +$1.5M 0.04% 397
2022
Q2 		– Sell
-9,868
Closed -$336K – 530
2022
Q1 		$336K Buy
9,868
+2,724
+38% +$87.1K 0.01% 420
2021
Q4 		$276K Buy
+7,144
New +$311K 0.02% 488

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TwinBeech Capital's CLDX Position: Q2 2026 in Review

TwinBeech Capital sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 11,445 shares — an estimated $363K sold.

TwinBeech Capital first reported a position in CLDX in Q4 2021 and held it in 14 quarters. The position peaked at $4.78M in Q3 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • TwinBeech Capital reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
  • TwinBeech Capital sold 11,445 Celldex Therapeutics shares in Q2 2026, an estimated $363K.
  • TwinBeech Capital first reported a position in Celldex Therapeutics in Q4 2021 and held it in 14 quarters.
  • TwinBeech Capital's Celldex Therapeutics position peaked at $4.78M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.